Delivery Order SPE2DB22D2211-SPE2DB25FSBTE
- Not listed
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Doxycycline Hyclate 100 mg tablets in quantities of 1,000 units. This competitively awarded, non-set-aside contract carries a ceiling value of $2,460.00 with firm fixed pricing and an ultimate completion date of July 24, 2025. The pharmaceutical products will be performed and delivered from the contractor's corporate office location in Conshohocken,...
- On July 21, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,268.75 to AmerisourceBergen Drug Corp for 1,000 tablets of Doxycycline Hyclate 100 mg. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of July 22, 2025. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this work at its Corporate Office location. This delivery order represents a routine...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $2,077.68 for 500 tablets of Doxycycline Hyclate 100 mg on July 22, 2025, with completion expected by July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Doxycycline 50 mg tablets (60-count) with a ceiling value of $7,399.24 under a firm fixed-price contract type. The award was issued on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen's Corporate Office division, headquartered in Conshohocken, Pennsylvania, is the location of performance for this pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,099.86 to AmerisourceBergen Drug Corp for the supply of Doxycycline 50 mg tablets (60-count packages) with an ultimate completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Doxycycline Hyclate 100 mg tablets in quantities of 1,000 units at a firm fixed price ceiling value of $2,952.00. This contract, awarded on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a non-set-aside competitive award. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,136.93 to AmerisourceBergen Drug Corp for the supply of Doxycycline Monohydrate 100 mg capsules in unit-dose packaging of 30 tablets. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded and completed on July 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical supply arrangement. This delivery order is issued...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,575.24, is for the delivery of 1,000 units of Doxycycline Hyclate 100 mg tablets. The contract has an ultimate completion date of June 16, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- The Defense Logistics Agency awarded a $20,468.22 delivery order to AmerisourceBergen Drug Corp for 60-tablet units of Doxycycline 50 mg on July 29, 2025, with an ultimate completion date of July 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,560,074,952 units of Doxycycline Hyclate 100mg tablets. The $2,209.34 firm fixed-price contract has a period of performance through February 28, 2023. This order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., valued at up to $999,999,999.00 and running through November...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSBTEDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Doxycycline Hyclate 100 mg tablets in quantities of 500 units, with a contract value of $1,080.00. The award was made on July 29, 2025, with an ultimate completion date of July 30, 2025, under a firm fixed-price delivery order with no set-aside designation. Performance will occur at the vendor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen Drug Corp's role as a critical pharmaceutical supplier to federal defense and healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare programs worldwide. As a competitively awarded contract without set-aside protections, this award reflects the vendor's demonstrated capability to fulfill federal medical procurement requirements for critical pharmaceutical commodities supporting Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 7/29/25 |